White label peptides - the supplier gives you vials, here's the other 80%

If you're researching "white label peptides," you've probably already found a supplier. This page is about everything the supplier's sales rep didn't mention - the storefront, the copy, the payment rails, and the paper trail that decide whether your brand survives its first year.

How white-label peptide supply actually works

The model is simple. A manufacturer or large importer runs the synthesis, lyophilization, and vialing. You pick compounds from their catalog, they apply your label art, and they ship you sealed, branded inventory - or hold it and drop-ship per order. Typical terms in 2026 look like this:

• Minimums - usually 50-100 vials per compound per size, sometimes 25 for a first test order. Per-vial cost commonly lands between $8 and $35 depending on compound and volume.
• Label service - they print and apply your artwork. Most suppliers require the research-use-only statement on the label and will reject art without it.
• Turnaround - 2-6 weeks for a first branded run; faster on reorders of stocked compounds.
• Testing - a certificate of analysis, sometimes per catalog batch rather than per your specific lot. That distinction matters later.

That's the whole product. Notice what's not in the list: a website, checkout, a payment processor that will keep you, compliant product copy, order-consent records, or a fulfillment loop that ties a shipped order to a specific tested lot. Every one of those is your problem, and every one of them has ended more peptide brands than bad inventory ever has.

The supplier landscape, honestly surveyed

Suppliers cluster into three tiers, and the tier you pick sets your risk floor:

• Domestic vialing houses - US-based, purchase orders and invoices, per-lot testing available if you ask and pay. Highest per-vial cost, cleanest paper trail.
• Import-and-relabel operations - overseas synthesis, US relabeling. Cheaper, and quality varies batch to batch. Demand third-party testing on your actual lots, not the supplier's house certificate.
• Direct-from-overseas - lowest cost, longest lead times, customs risk on you, and testing claims you can't verify without paying an independent lab yourself. Fine for some operators, but understand you are the importer of record.

Two diligence checks separate real suppliers from resellers cosplaying as manufacturers. First: ask for a per-lot COA from a named third-party lab, with the lab's report number you can verify directly. A supplier who only offers a generic "99% purity" PDF with no lab name is testing nothing. Second: ask what happens if the FDA sends you a letter citing one of their compounds. A serious supplier has an answer about recalls and lot tracing. A reseller changes the subject.

One more filter that saves brands later: check your candidate catalog against the compounds the FDA has actually cited. The agency sent warning letters to seven peptide sellers on March 31, 2026 alone, and letters routinely name specific compounds - semaglutide, tirzepatide, and retatrutide appear constantly. We keep a running breakdown in the warning-letter guide. If a supplier pushes GLP-1s on you as their best sellers, that's not an opportunity - that's the single highest-enforcement category in the space, and no label design changes what the compound is.

What the supplier contract covers - and the 80% it doesn't

Lay the two lists side by side and the gap is obvious:

By parts count that's maybe 20% supplied, 80% open. Here are the four gaps in the order they usually kill brands.

Gap 1: the compliant storefront and copy

The FDA doesn't judge your label in isolation - it judges the totality of your site under the intended-use doctrine. Product names, descriptions, blog posts, FAQ answers, even image alt text: if the whole reads as "this is for people to use," the RUO line on the vial is decoration. The 2024 letter to Summit Research Peptides and the 2025 letter to Pinnacle Peptides both cited marketing language, not just the compounds. The 2026 letters to Gram Peptides, Prime Sciences, and Pekcura Labs repeated the pattern - and in the Gram case the agency pierced code-named product listings, so renaming a compound protects nothing.

This is where white-label operators get burned worst, because the supplier hands them zero copy. They write their own, they borrow phrasing from bigger stores (many of which are themselves one letter away from trouble), and they ship benefit claims without knowing it. The fix is structural: every copy surface goes through a linter that blocks human-use, dosing, and disease language before it publishes - enforced in code, not memory. If you're choosing how to build the site itself, the peptide website builder comparison covers why the mainstream platforms can't do this, and the full start-a-company guide puts the storefront in sequence with everything else.

Gap 2: payment rails that survive

The predictable failure: launch on a mainstream processor, run fine for two or three weeks, then take the termination email. Stripe, Square, and PayPal all prohibit the category; Shopify Payments follows Stripe's rules. Termination usually comes with funds held 90-180 days, and a termination logged to the MATCH list follows you to every acquirer you apply to afterward. Card-network pressure runs the same direction - Visa's integrity-risk program makes high-risk RUO merchants expensive for acquirers to keep, so even "high-risk friendly" processors enforce chargeback ceilings around 1%-1.5%.

Your supplier has a working merchant account for their wholesale business. That does nothing for your retail storefront - underwriting is per-merchant, per-site. Plan payment rails as a first-class launch task: a properly underwritten high-risk account where you disclose exactly what you sell, plus fallback rails, plus a site the underwriter can look at without flinching. Budget for it too - the real cost breakdown shows payments and compliance, not inventory, are where the actual money goes.

Gap 3: consent logging, gates, and the legal surface

A defensible RUO store isn't a disclaimer in the footer. It's a set of mechanisms that produce records:

• Age and qualified-researcher gate on entry, on every page load path - not just the homepage.
• Order-level consent - a logged, timestamped acknowledgment attached to each order, not a checkbox that vanishes into nothing. If you're ever asked to demonstrate your controls, "we have a banner" is not an answer; "here is the consent record for order #4127" is.
• RUO disclosure on every page, rendered by the layout so no one can forget it on a new page.
• A product-intake guardrail that structurally refuses the compounds that draw letters, so a rushed 11pm catalog upload can't create your worst liability.

None of this comes from the supplier, and none of it exists in a stock Shopify or WooCommerce theme. It has to be built into the store's code, because the honest truth about compliance is that anything enforced by memory eventually fails - usually the week you're busiest. Mid-diligence tip: run any established competitor through a 60-second compliance audit and look at what a store that's survived actually carries. That's the bar your day-one site has to meet, because enforcement doesn't grade on a curve for new brands.

Gap 4: fulfillment integration and per-lot COAs

Two operational questions decide whether your back office is real:

Who ships, and how does your store know? If the supplier drop-ships, you need order data flowing to them and tracking flowing back, automatically - manual CSV emails break by week four. If you hold inventory, you need live carrier rates, label purchase, and delivery tracking wired into the storefront. The peptide dropshipping guide walks the supplier-ships model honestly, including the part where you still own every compliance obligation even when you never touch a vial.

Can a customer trace their vial to a test? Per-lot COAs, published on your site, mapped to the specific lots you shipped. This is both a trust signal that measurably converts and part of your defense posture. It requires a real pipeline: supplier sends lot documents, you verify the lab and report number, the store links each product batch to its certificate, and superseded lots stay archived rather than silently vanishing. A folder of PDFs on a "Lab Results" page mapped to nothing is what most white-label brands ship - and it's worth almost nothing.

The launch sequence that closes all four gaps

1. Pick the supplier last-but-one, not first. Shortlist two, get per-lot testing terms in writing, screen the catalog against the do-not-list compounds before you wire anything.
2. Build the storefront with compliance in the code - linter on copy, guardrail on products, gates and consent logging on by default. This is the long pole; start it before inventory lands.
3. Underwrite payments in parallel - honest application, real high-risk acquirer, fallback rail configured before launch, not after the first termination.
4. Wire fulfillment and the COA pipeline - order flow to whoever ships, tracking back to the customer, every lot mapped to a verifiable certificate.
5. Then place the branded inventory order. Vials arriving before the store is defensible just means capital sitting in boxes while the actual bottleneck gets solved.

Run in that order, gap two and gap one stop being emergencies. Run in the usual order - inventory first, everything else improvised - and you're the brand with $6,000 of labeled stock and no way to take a card payment.

Questions, answered straight

This guide is general information for store operators, not legal advice.